Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controls

Schizophrenia Research

Volumn 104, Issue 1-3, 2008, Pages 36-43

  Lee, Bun Hee ^a   Kim, Yong Ku ^a,b  

^a Korea University College of Medicine   (South Korea)

^b Korea University   (South Korea)

Author keywords

Nitric oxide; Risperidone; Schizophrenia

Indexed keywords

BENZATROPINE; LORAZEPAM; NITRIC OXIDE; RISPERIDONE;

ADULT; ANXIETY DISORDER; ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DISEASE SEVERITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; METABOLITE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SLEEP DISORDER; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ELECTROCARDIOGRAPHY; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; MALE; NITRIC OXIDE; RISPERIDONE; SCHIZOPHRENIA;

EID: 50549088246     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.06.005     Document Type: Article

References (47)

1. Akyol O., Zoroglu S.S., Armutcu F., Sahin S., and Gurel A. Nitric oxide as a physiopathological factor in neuropsychiatric disorders. In Vivo 18 3 (2004) 377-390
2. Andreasen N.C., Rezai K., Alliger R., Swayze V.W.n., Flaum M., Kirchner P., Cohen G., and O'Leary D.S. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch. Gen. Psychiatry 49 12 (1992) 943-958
3. American Psychiatric Association. DSM-IV:Diagnostic and Statistical Manual of Mental Disorders. Fourth ed (1994), American Psychiatric Press, Washington DC
4. Baba H., Suzuki T., Arai H., and Emson P.C. Expression of nNOS and soluble guanylate cyclase in schizophrenic brain. Neuroreport 15 4 (2004) 677-680
5. Barañano D.E., and Snyder S.H. Neural roles for heme oxygenase: contrasts to nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 98 20 (2001) 10996-11002
6. Bernstein H.G., Bogerts B., and Keilhoff G. The many faces of nitric oxide in schizophrenia. A review. Schizophr. Res. 78 1 (2005) 69-86
7. Bird D.C., Bujas-Bobanovic M., Robertson H.A., and Dursun S.M. Lack of phencyclidine-induced effects in mice with reduced neuronal nitric oxide synthase. Psychopharmacology (Berl) 155 3 (2001) 299-309
8. Bonfoco E., Krainc D., Ankarcrona M., Nicotera P., and Lipton S.A. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-d-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 7162-7166
9. Brenman J.E., and Bredt D.S. Synaptic signaling by nitric oxide. Curr. Opin. Neurobiol. 7 3 (1997) 374-378
10. Brewer W.J., Yücel M., Harrison B.J., McGorry P.D., Olver J., Egan G.F., Velakoulis D., and Pantelis C. Increased prefrontal cerebral blood flow in first-episode schizophrenia following treatment: longitudinal positron emission tomography study. Aust. N. Z. J. Psychiatry 41 2 (2007) 129-135
11. Bujas-Bobanovic M., Bird D.C., Robertson H.A., and Dursun S.M. Blockade of phencyclidine-induced effects by a nitric oxide donor. Br. J. Pharmacol. 130 5 (2000) 1005-1012
12. Bujas-Bobanovic M., Robertson H.A., and Dursun S.M. Effects of nitric oxide synthase inhibitor N(G)-nitro-l-arginine methyl ester on phencyclidine-induced effects in rats. Eur. J. Pharmacol. 409 1 (2000) 57-65
13. Carlsson A., Hansson L.O., Waters N., and Carlsson M.L. A glutamatergic deficiency model of schizophrenia. Br. J. Psychiatr., Suppl. 37 (1999) 2-6
14. Das I., Khan N.S., Puri B.K., and Hirsch S.R. Elevated endogenous nitric oxide synthase inhibitor in schizophrenic plasma may reflect abnormalities in brain nitric oxide production. Neurosci. Lett. 215 3 (1996) 209-211
15. Das I., Khan N.S., Puri B.K., Sooranna S.R., Belleroche J.d., and Hirsch S.R. Elevated platelet calcium mobilization and nitric oxide synthase activity may reflect abnormalities in schizophrenic brain. Biochem. Biophys. Res. Commun. 212 2 (1995) 375-380
16. Das I., Ramchand C.N., Gliddon A., and Hirsch S.R. Nitric oxide, free radicals and polyamines may have a role in the membrane pathology of schizophrenia. Neuropsychobiology 37 2 (1998) 65-67
17. Fiddler R.M. Collaborative study of modified AOAC method of analysis for nitrite in meat and meat products. J. AOAC 60 (1977) 594
18. First M., Spitzer R.L., Gibbon M., and William J.B. Structured Clinical Interview for DSM-IV Axis I Disorder - Patient Edition(SCID-I/P, version 2.0) (1998), Biometrics Research Department, New York State Psychiatric Institute, New York
19. Guix F.X., Uribesalgo I., Coma M., and Munoz F.J. The physiology and pathophysiology of nitric oxide in the brain. Prog. Neurobiol. 76 2 (2005) 126-152
20. Herken H., Uz E., Ozyurt H., and Akyol O. Red blood cell nitric oxide levels in patients with schizophrenia. Schizophr. Res. 52 3 (2001) 289-290
21. Kato T., Monji A., Hashioka S., and Kanba S. Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro. Schizophr. Res. 92 1-3 (2007) 108115
22. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull 13 2 (1987) 261-276
23. Klamer D., Engel J.A., and Svensson L. Effects of phencyclidine on acoustic startle and prepulse inhibition in neuronal nitric oxide synthase deficient mice. Eur. Neuropsychopharmacol. 15 5 (2005) 587-590
24. Klamer D., Zhang J., Engel J.A., and Svensson L. Selective interaction of nitric oxide synthase inhibition with phencyclidine: behavioural and NMDA receptor binding studies in the rat. Behav. Brain. Res. 159 1 (2005) 95-103
25. Liddle P.F., Friston K.J., Frith C.D., Hirsch S.R., Jones T., and Frackowiak R.S. Patterns of cerebral blood flow in schizophrenia. Br. J. Psychiatry 160 (1992) 179-186
26. McLeod T.M., Lopez-Figueroa A.L., and Lopez-Figueroa M.O. Nitric oxide, stress, and depression. Psychopharmacol. Bull. 35 1 (2001) 24-41
27. Montague P.R., Gancayco C.D., Winn M.J., Marchase R.B., and Friedlander J. Role of NO production in NMDA receptor-mediated neurotransmitter release in cerebral cortex. Science 263 (1994) 973-977
28. Nelson R.J., Kriegsfeld L.J., Dawson V.L., and Dawson T.M. Effects of nitric oxide on neuroendocrine function and behavior. Front. Neuroendocrinol. 18 (1997) 463-491
29. Osawa Y., and Davila J.C. Phencyclidine, a psychotomimetic agent and drug of abuse, is a suicide inhibitor of brain nitric oxide synthase. Biochem. Biophys. Res. Commun. 194 3 (1993) 1435-1439
30. Pogun S., and Kuhar M.J. Regulation of neurotransmitter reuptake by nitric oxide. Ann. N. Y. Acad. Sci. 738 (1994) 305-315
31. Ramirez J., Garnica R., Boll M.C., Montes S., and Rios C. Low concentration of nitrite and nitrate in the cerebrospinal fluid from schizophrenic patients: a pilot study. Schizophr. Res. 68 2-3 (2004) 357-361
32. Richardson M.A., Read L.L., Clelland C.L.T., Reilly M.A., Chao H.M., Guynn R.W., Suckow R.F., and Clelland J.D. Evidence for a tetrahydrobiopterin deficit in schizophrenia. Neuropsychobiology 52 4 (2005) 190-201
33. Richardson M.A., Read L.L., Reilly M.A., Clelland J.D., and Clelland C.L. Analysis of plasma biopterin levels in psychiatric disorders suggests a common BH4 deficit in schizophrenia and schizoaffective disorder. Neurochem. Res. 32 1 (2007) 107-113
34. Sams-Dodd F. Effects of continuous d-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats. Neuropsychopharmacology 19 1 (1998) 18-25
35. Snitz B.E., MacDonald 3rd A., Cohen J.D., Cho R.Y., Becker T., and Carter C.S. Lateral and medial hypofrontality in first-episode schizophrenia: functional activity in a medication-naive state and effects of short-term atypical antipsychotic treatment. Am. J. Psychiatry 162 12 (2005) 2322-2329
36. Srivastava N., Barthwal M.K., Dalal P.K., Agarwal A.K., Nag D., Srimal R.C., Seth P.K., and Dikshit M. Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacology (Berl) 158 2 (2001) 140-145
37. Suzuki E., Yagi G., Nakaki T., Kahba S., and Asai M. Elevated plasma nitrate levels in depressive states. J. Affect. Disord. 63 (2001) 221-224
38. Suzuki E., Nakaki T., Shintani F., Kanba S., and Miyaoka H. Antipsychotic, antidepressant, anxiolytic, and anticonvulsant drugs induce type II nitric oxide synthase mRNA in rat brain. Neurosci. Lett. 333 3 (2002) 217-219
39. Suzuki E., Nakaki T., Nakamura M., and Miyaoka H. Plasma nitrate levels in deficit versus non-deficit forms of schizophrenia. J. Psychiatry Neurosci. 28 4 (2003) 288-292
40. Taneli F., Pirildar S., Akdeniz F., Uyanik B.S., and Ari Z. Serum nitric oxide metabolite levels and the effect of antipsychotic therapy in schizophrenia. Arch. Med. Res. 35 5 (2004) 401-405
41. Tarazi F.I., Zhang K., and Baldessarini R.J. Long-term effects of newer antipsychotic drugs on neuronal nitric oxide synthase in rat brain. Nitric Oxide 7 4 (2002) 297-300
42. Tsikas D. Analysis of nitrite and nitrate in biological fluids by assays based on the Griess reaction: appraisal of the Griess reaction in the l-arginine/nitric oxide area of research. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 851 1-2 (2007) 51-70
43. Vita A., and De Peri L. The effects of antipsychotic treatment on cerebral structure and function in schizophrenia. Int. Rev. Psychiatry 19 4 (2007) 429-436
44. Xing G., Chavko M., Zhang L.X., Yang S., and Post R.M. Decreased calcium-dependent constitutive nitric oxide synthase (cNOS) activity in prefrontal cortex in schizophrenia and depression. Schizophr. Res. 58 1 (2002) 21-30
45. Yamada K., Noda Y., Nakayama S., Komori Y., Sugihara H., Hasegawa T., and Nabeshima T. Role of nitric oxide in learning and memory and in monoamine metabolism in the rat brain. Br. J. Pharmacol. 115 (1995) 852-858
46. Yao J.K., Leonard S., and Reddy R.D. Increased nitric oxide radicals in postmortem brain from patients with schizophrenia. Schizophr. Bull. 30 4 (2004) 923-934
47. Yermolaieva O., Brot N., Weissbach H., Heinemann S.H., and Hoshi T. Reactive oxygen species and nitric oxide mediate plasticity of neuronal calcium signaling. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 448-453